(Q53076367)

11 May 2018

title

Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. (English)

1 reference

11 May 2018

author

Raphaël Porcher

4

1 reference

11 May 2018

author name string

David Groheux

1

1 reference

11 May 2018

Sylvie Giacchetti

2

1 reference

11 May 2018

Jean-Luc Moretti

3

1 reference

11 May 2018

Marc Espié

5

1 reference

11 May 2018

Jacqueline Lehmann-Che

6

1 reference

11 May 2018

Anne de Roquancourt

7

1 reference

11 May 2018

Anne-Sophie Hamy

8

1 reference

11 May 2018

Caroline Cuvier

9

1 reference

11 May 2018

Laetitia Vercellino

10

1 reference

11 May 2018

Elif Hindié

11

1 reference

11 May 2018

publication date

6 November 2010

1 reference

11 May 2018

European Journal of Nuclear Medicine and Molecular Imaging

published in

1 reference

11 May 2018

volume

38

1 reference

11 May 2018

issue

3

1 reference

11 May 2018

page(s)

426-435

1 reference

11 May 2018

https://scigraph.springernature.com/pub.10.1007/s00259-010-1640-9

exact match

0 references

cites work

FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Revision of the American Joint Committee on Cancer staging system for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

A simple p53 functional assay for screening cell lines, blood, and tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Biological characterisation of breast cancer by means of PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

TIGAR, a p53-inducible regulator of glycolysis and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Triple negative breast cancers: clinical and prognostic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Gene expression patterns associated with p53 status in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Prognostic markers in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1640-9

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

21 January 2018

1 reference

12 December 2020

The relationship between FDG uptake in PET scans and biological behavior in breast cancer

1 reference

12 December 2020

The evolving role of PET/CT in breast cancer

1 reference

12 December 2020

Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.

1 reference

12 December 2020

HER2 status and benefit from adjuvant trastuzumab in breast cancer

1 reference

12 December 2020

Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.

1 reference

12 December 2020

Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations

1 reference

12 December 2020

Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro

1 reference

12 December 2020

High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases

1 reference

12 December 2020

Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose

1 reference

12 December 2020

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy

1 reference

12 December 2020

Expression of glucose transporter GLUT-1 and estrogen receptors ER-alpha and ER-beta in human breast cancer

1 reference

12 December 2020

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

1 reference

12 December 2020

Association between [ 18 F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation

1 reference

12 December 2020

Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors

1 reference

12 December 2020

10.1007/S00259-010-1640-9

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018